Augmented APOA1 reflects its potential role in driving therapeutic resistance and disease progression by reprogramming the lipid metabolic network of tumor cells [52]; APOB, APOC3, and APOH may function like APOA1. This evidence concerns the gene APOC3 and neoplasm.